Trial · NCT03331250
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
NCT03331250, Phase 2, Completed, Massachusetts General Hospital; results first posted 2024-11-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Trials, record NCT03331250. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03331250
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
- NCT number
- NCT03331250
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Angiosarcoma, Epithelioid Hemangioendothelioma
- Interventions
- Eribulin
- First posted
- 2017-11-06
- Last updated
- 2026-08-28
- Results first posted
- 2024-11-08
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | 2 years | The ORR is defined as the percentage of patients who achieved a partial response or complete response by RECIST 1.1. Tumor imaging studies were completed using either CT (Computed Tomography) or MRI (Magnetic resonance imaging). The modality chosen for any individual patient was the same from baseline until the end of their time on study. Per RECIST v 1.1, complete response (CR) is defined as the disappearance of all target lesions and the reduction in any pathological lymph nodes in short axis to less than 10 mm. Partial response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions compared with baseline. Progressive disease (PD) is defined as a 20% increase (5+ mm absolute increase) compared with the smallest sum on study. Stable disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor PD. |
| Secondary | Progression Free Survival | All AEs were collected from cycle 1 day 1 until either 28 days after the subject's last dose (an average 37 weeks), or resolution/stabilization of an AE if continuing beyond 28 days. | Progression-free survival, will be defined as the duration of time from start of treatment to time of progression or death, whichever occurs first and will be estimated using the Kaplan-Meier method. |
| Secondary | Disease Control Rate | 24 weeks | Objective Response plus Stable Disease Rate at 24 weeks |
| Secondary | Treatment Related Adverse Events | All AEs were collected from cycle 1 day 1 until either 28 days after the subject's last dose (an average 37 weeks). | Summary of the treatment related adverse events experienced by study participants as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4). Grade 3+ only. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate (ORR) | 2 years | One patient out of the 13 who enrolled withdrew from the study before completing any cycles of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Progression Free Survival | 4 years | |||
| SECONDARY | Disease Control Rate | 24 weeks | |||
| SECONDARY | Treatment Related Adverse Events | 4 years |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Eribulin | 4 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Eribulin | 13 | |
| Overall Study | COMPLETED | Eribulin | 12 | |
| Overall Study | NOT COMPLETED | Eribulin | 1 |
Source ClinicalTrials.gov
Adverse events76
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Eribulin | 2 | 13 | |
| other | Alanine aminotransferase increased | Investigations | Eribulin | 2 | 13 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Eribulin | 4 | 13 | |
| other | Anemia | Blood and lymphatic system disorders | Eribulin | 6 | 13 | |
| other | Anorexia | Metabolism and nutrition disorders | Eribulin | 2 | 13 | |
| other | Anxiety | Psychiatric disorders | Eribulin | 1 | 13 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Eribulin | 2 | 13 | |
| other | Aspartate aminotransferase increased | Investigations | Eribulin | 2 | 13 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Eribulin | 2 | 13 | |
| other | Bloating | Gastrointestinal disorders | Eribulin | 1 | 13 |
1 to 10 of 76Source ClinicalTrials.gov
See all 76 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Eribulin | 11 | 13 |
| Total, other adverse events | Eribulin | 13 | 13 |
| Total, serious adverse events | Eribulin | 3 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03331250
GET https://conductscience.org/api/trials/v1/NCT03331250/events?page=2